Drugs / trifluridine/tipiracil
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07012954 Background | Jun 2025 → Dec 2027 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07012954 ↗ |
| Route | Oral | “Trifluridine/tipiracil 35 mg/m² (orally for 5 days, followed by 9 days off)” NCT07012954 ↗ |